Literature DB >> 3091637

Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture.

J Buxbaum.   

Abstract

Bone marrow cells obtained from 14 patients with light chain amyloid (AL) deposition were examined by biosynthetic labeling techniques. These analyses identified free monoclonal light chain (L-chain) synthesis even in those patients whose serum or urine contained no M protein or free L-chains or only an intact M protein. The experiments also identified a subset of patients whose plasma cells synthesized polypeptides bearing constant region antigenic determinants that migrated more rapidly than intact L-chains on polyacrylamide gels. Since most AL fibrils contain L-chain fragments rather than intact L-chains, these studies suggested that the genesis of the fibril components may reflect aberrant synthesis, proteolytic processing, or both. We also noted that in some individuals the pattern of Ig synthesis normalized after several courses of cytotoxic therapy. Thus, we could use bone marrow Ig synthesis as a sensitive biochemical parameter for monitoring therapy. Finally, the presence of aberrant synthetic products in these clones raised questions about their origin with respect to the normal processes of transcription, translation, and posttranslational modification in Ig-producing cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091637      PMCID: PMC423678          DOI: 10.1172/JCI112643

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Counting actively metabolizing tissue cultured cells.

Authors:  H J PHILLIPS; J E TERRYBERRY
Journal:  Exp Cell Res       Date:  1957-10       Impact factor: 3.905

2.  Low-molecular-weight proteins related to Bence Jones proteins in multiple myeloma.

Authors:  A Solomon; J Killander; H M Grey; H G Kunkel
Journal:  Science       Date:  1966-03-11       Impact factor: 47.728

3.  Localization of the carbohydrate within the variable region of light and heavy chains of human gamma g myeloma proteins.

Authors:  H L Spiegelberg; C A Abel; B G Fishkin; H M Grey
Journal:  Biochemistry       Date:  1970-10-13       Impact factor: 3.162

4.  Preparation of mammalian polyribosomes with the detergent Nonidet P-40.

Authors:  T W Borun; M D Scharff; E Robbins
Journal:  Biochim Biophys Acta       Date:  1967-11-21

5.  Molecular characterization of a nonsecreting myeloma mutant.

Authors:  Y Argon; O R Burrone; C Milstein
Journal:  Eur J Immunol       Date:  1983-04       Impact factor: 5.532

6.  Low molecular weight L-chain components related to Bence-Jones proteins.

Authors:  R C Williams; S R Pinnell; G T Bratt
Journal:  J Lab Clin Med       Date:  1966-07

7.  Attachment of carbohydrate to the variable region of myeloma immunoglobulin light chains.

Authors:  H C Sox; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1970-07       Impact factor: 11.205

Review 8.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

9.  Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda).

Authors:  A Solomon; B Frangione; E C Franklin
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

10.  Human myeloma light chains with increased molecular weight: high frequency among lambda chains.

Authors:  J P Bouvet; J Pillot; P Liacopoulos
Journal:  Mol Immunol       Date:  1983-04       Impact factor: 4.407

View more
  15 in total

1.  Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease.

Authors:  M Cogné; J L Preud'homme; M Bauwens; G Touchard; P Aucouturier
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig.

Authors:  J E Hopper; J Golbus; C Meyer; G A Ferrer
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

3.  Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.

Authors:  Boris Brumshtein; Shannon R Esswein; Michael R Sawaya; Gregory Rosenberg; Alan T Ly; Meytal Landau; David S Eisenberg
Journal:  J Biol Chem       Date:  2018-10-24       Impact factor: 5.157

4.  Formation of amyloid fibers by monomeric light chain variable domains.

Authors:  Boris Brumshtein; Shannon R Esswein; Meytal Landau; Christopher M Ryan; Julian P Whitelegge; Martin L Phillips; Duilio Cascio; Michael R Sawaya; David S Eisenberg
Journal:  J Biol Chem       Date:  2014-08-19       Impact factor: 5.157

Review 5.  Frequency and genetic background of the position 122 (Val----Ile) variant transthyretin gene in the black population.

Authors:  D R Jacobson; J D Reveille; J N Buxbaum
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

Review 6.  Treatment of immunoglobulin light chain amyloidosis.

Authors:  Morie A Gertz; Steven R Zeldenrust
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

Review 7.  Systemic amyloidoses.

Authors:  Luis M Blancas-Mejía; Marina Ramirez-Alvarado
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643

8.  Induction in mice of human light-chain-associated amyloidosis.

Authors:  A Solomon; D T Weiss; M B Pepys
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

9.  Light chain-associated amyloid deposits comprised of a novel kappa constant domain.

Authors:  A Solomon; D T Weiss; C L Murphy; R Hrncic; J S Wall; M Schell
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.

Authors:  Pamina Kazman; Marie-Theres Vielberg; María Daniela Pulido Cendales; Lioba Hunziger; Benedikt Weber; Ute Hegenbart; Martin Zacharias; Rolf Köhler; Stefan Schönland; Michael Groll; Johannes Buchner
Journal:  Elife       Date:  2020-03-10       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.